trial · primary record
Firmonertinib
Non-Small-Cell Lung Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 480 |
| Primary completion | 2030-12 |
| Primary endpoint | Progression Free Survival (PFS) determined by blinded independent central review (BICR) |
| Registry ID | NCT07185997 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:46.983Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07185997
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.